drugset

drugset / Trial / NCT00697281

OC000459 Dose Finding Study in Hay Fever Sufferers.

NCT00697281 ↗

Phase 2 Completed 120 enrolled Oxagen Ltd

RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to evaluate a range of dose levels for efficacy in the control of symptoms of allergic rhinitis

Timeline

Start: 2008-05
Primary completion: 2008-07
Completion: 2008-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TIMAPIPRANT	Small molecule	—	Oral

Indications